Introduction
============

Ocular melanoma accounts for 3% of all melanoma cases [@b1]. Uveal melanoma (UM) is the most common primary intraocular tumor with an incidence of approximately five cases per million individuals [@b1]. Up to 50% of patients develop metastatic disease with spread of tumor cells to liver (89%), lung (29%), bone (17%), and other organs [@b1],[@b2]. At this stage UM has a poor prognosis with median overall survival (OS) of 4--15 months [@b3]. Survival rates in metastatic UM (MUM) have remained almost unchanged in the past 40 years [@b1].

As far as MUM is restricted to a limited anatomic region, locoregional treatment modalities can be used to control disease, for example, surgical resection, intraarterial chemotherapy, transarterial percutaneous chemoembolization, selective internal radiation therapy, and radiofrequency ablation [@b4]. Patients in whom surgical resection is feasible show longer OS [@b5]. Liver-directed therapies may induce remission of single metastases but do not prolong OS [@b4].

MUM is frequently treated with chemotherapeutics like dacarbazine, fotemustine, or gemcitabine/treosulfan although evidence for these regimens is limited. In clinical practice, responses are rarely seen and the impact of systemic chemotherapy on patients\' survival is questionable [@b3].

Our understanding of molecular genetics and intracellular signaling pathways involved in the pathogenesis of MUM has improved over the last decades [@b6] resulting in the current investigation of targeted therapy approaches. We here review the present status of systemic treatment of MUM and evaluate therapy outcome measured by overall response rate (ORR) (IBM, Ehningen, Germany).

Methods
=======

PubMed search was performed for "metastatic" \[and\] "uveal" \[and\] "melanoma" as well as for "melanoma" \[and\] "eye" \[and\] "treatment" on 16 May 2013 for the time period between 1980 and May 2013. "Web of Knowledge" and congress abstract search via the American Society of Clinical Oncology homepage was performed (data cut 22 May 2013). The <http://ClinicalTrials.gov> website was searched for terms "melanoma" and "eye" on 13 May 2013. All retrieved study summaries were screened and compared to published data.

All titles and abstracts in English language were screened for relevant content by the first author (K. B.). The selection process was documented according to PRISMA criteria (Fig. [1](#fig01){ref-type="fig"}) [@b7]. Studies on in vitro data, diagnostics, treatment of the primary tumor, single case reports, and clinical trials on locoregional treatment modalities were excluded. Full text versions of all relevant articles in English language were obtained and their references reviewed for additional relevant reports. Studies with less than four MUM patients, ecological design, without description of objective response assessment and studies not reporting ORR were excluded from meta-analysis (Fig. [1](#fig01){ref-type="fig"}). All remaining studies were reviewed for quality aspects including study design, patient population, histological confirmation of disease, and method of staging/outcome evaluation by first and second author (K. B., A. G.). Patients treated in higher than first-line situations were classified as "non-first-line."

![Flow of information through the different phases of the review process according to PRISMA statement [@b7].](cam40002-0674-f1){#fig01}

Studies were grouped by type of treatment into single-agent or combination chemotherapies, chemoimmunotherapies, immunotherapies, antiangiogenetic therapies, and treatment with kinase inhibitors. In each group, rates of complete (CR) or partial remission (PR) and their exact 95% confidence intervals (95% CI) were computed for each study and overall for the group. In addition, homogeneity of ORR was examined by the exact chi-squared test. In case that homogeneity was rejected, the ORR was computed again, excluding the outlier study that caused heterogeneity. An overall summary analysis was carried out equally for all types of treatment. Statistical analysis was performed using SPSS statistics program version 21.0 (IBM, Ehningen, Germany).

Results
=======

The selection process is outlined in Figure [1](#fig01){ref-type="fig"}. Of 59 retrieved articles including 11 congress abstracts, four were excluded because of small patient numbers (*n* \< 4) [@b8]--[@b10] or ecological design [@b2]. Nine were excluded because ORR was not reported [@b11]--[@b15] or mixture study design did not permit separate analysis of MUM data [@b16]--[@b19]. Forty-six studies were included in review discussion, that is, one case series, five pilot, three phase I, one phase I/II, 29 phase II, and one phase III study, data from three expanded access programs, and four retrospective data analyses. In six of the studies response criteria were insufficiently described. The first authors of these reports were contacted by e-mail to comment on response criteria. In case of authors\' response studies were included in numeric analysis [@b20]--[@b22] while studies for which response criteria could not be elucidated were excluded [@b23]--[@b25]. Two publications were excluded because of presentation-driven interim analyses of incomplete clinical trials, one of them reported within a review publication [@b26],[@b27] (NCT00338130, NCT01143402). One publication was excluded from numeric analysis because the drug could not be assigned to one treatment subgroup [@b28].

The numeric analysis included 40 publications with a total of 841 patients (Table [1](#tbl1){ref-type="table"}). Patient numbers ranged from four in a pilot study [@b29] to 171 patients in a randomized multicenter study [@b30]. Histological confirmation of metastatic disease was reported in 19/40 studies. Immunohistochemical stains of c-kit were performed in one study [@b31], mutational analysis of c-kit in another study [@b32] and GNAQ sequencing in a limited number of patients in two studies [@b33],[@b34]. Mean patients\' age was 59 years; 546 patients were treated in first-line situation whereas 229 patients had received prior therapies including surgery, liver-directed treatment, chemotherapy, or immunotherapy. Response was evaluated according to WHO response criteria of 1979 [@b35] in 12 and according to RECIST 1.0/1.1 [@b36] in 27 studies.

###### 

Study characteristics.

  Author                   Year   Drug                                           Study design                    Response assessment                                     *n*      First-line   Non-first-line   Mean age   SD      PR/CR     ORR (%)   PFS (mon)   OS (mon)   Histology/genetics
  ------------------------ ------ ---------------------------------------------- ------------------------------- ------------------------------------------------------- -------- ------------ ---------------- ---------- ------- --------- --------- ----------- ---------- --------------------
  Spagnolo                 2013   Fotemustine                                    Retrospective                   RECIST                                                  24       24           0                62         9       2/0       8.3       unk         13.9       no/no
  Leyvraz                  2012   Fotemustine (iv vs. ia)                        Phase III                       RECIST                                                  83 (a)   83           0                59         unk     2/unk     2.4       3.7         unk        yes/no
  Homsi                    2010   DHA-paclitaxel                                 Phase II                        RECIST                                                  22       11           11               56         7       1/0       4.6       3.0         9.8        no/no
  Bedikian                 2008   Liposomal vincristine                          Pilot                           WHO                                                     4        unk          unk              56         unk     0/1 (b)   25.0      unk         unk        yes/no
  Schmidt-Hieber           2004   Bendamustine                                   Phase II                        RECIST                                                  11       0            11               61         0       0/0       0.0       unk         unk        yes/no
  Bedikian                 2003   Temozolomide                                   Phase II                        WHO                                                     14       9            5                53         2       0/0       0.0       1.8         6.7        no/no
  Ellerhorst               2002   Nitro-camptothecin                             Phase II                        WHO                                                     14       0            14               59         2       0/0       0.0       unk         unk        no/no
  Atzpodien                2008   Cisplatin (iv vs. ia)/gemcitabine/treosulfan   Pilot                           WHO                                                     12       1            11               62         6       0/0       0.0       unk         6.0        no/no
  O\'Neill                 2006   Dacarbacine/treosulfan                         Phase II                        RECIST                                                  14       15           0                64         2       0/0       0.0       3.0         7.5        no/no
  Schmittel (a)            2005   Cisplatin/gemcitabine/treosulfan               Phase II                        RECIST                                                  17       19           0                60         7       0/0       0.0       3.0         7.7        yes/no
  Flaherty                 1998   Diverse chemotherapies                         Retrospective pooled analysis   WHO                                                     64 (c)   unk          unk              59         unk     5/1       9.0       unk         5.2        no/no
  Sacco                    2013   Dacarbazine                                    Phase II, randomized            RECIST                                                  37       37           0                unk        4       3/unk     8.0       3.9         8.7        no/no
  Sunitinib                                                                      37                              37                                                      0        unk          9                0/0        0.0     2.8       6.4                              
  Schmittel                2006   Treosulfan                                     Phase II, randomized            RECIST                                                  24       17           7                58         3       0/0       0.0       2.0         unk        yes/no
  Gemcitabine/treosulfan                                                         24                              15                                                      9        63           7                0/1        4.2     3.0       unk                              
  Corrie                   2005   Gemcitabine/treosulfan                         Phase I                         RECIST                                                  5        4            1                50         4       0/0       0.0       6.8         13.3       yes/no
  Schmittel (b)            2005   Gemcitabine/treosulfan                         Phase II                        RECIST                                                  33       28           5                62         14      1/0       3.0       2.5         7.5        yes/no
  Terheyden                2004   Gemcitabine/treosulfan                         Phase II                        WHO                                                     20       8            14               62         5       0/0       0.0       unk         11.6       yes/no (d)
  Keilholz                 2004   Gemcitabine/treosulfan                         Phase I                         RECIST[1](#tf1-1){ref-type="table-fn"}                  33       28           5                62         15      1/0       3.0       unk         unk        yes/no
  Pföhler                  2003   Gemcitabine/treosulfan                         Pilot                           WHO                                                     14       13           1                63         8       3/1       28.6      7.1         15.3       no/no
  Kivelä                   2003   BOLD/INF-α2b                                   Phase II                        WHO                                                     22       24           0                61         2       0/0       0.0       1.9         10.6       yes/no
  Pyrhönen                 2002   BOLD/INF-α2b                                   Phase II                        WHO                                                     20       18           4                60         11      0/3       15.0      4.4         12.3       yes/no
  Becker                   2002   fotemustine/INF-α2b/IL-2                       Phase II                        WHO                                                     25       unk          unk              56         unk     1/1       8.0       unk         15.0 (e)   no/no
  Nathan                   1997   BOLD/INFα-2b                                   Phase II                        WHO                                                     20       23           0                62         unk     4/0       20.0      unk         unk        yes/no
  Kelderman                2013   Ipilimumab                                     EAP                             RECIST, irRC                                            22       0            22               54         1       1/0       4.5       2.9         5.2        no/no
  Khattak                  2013   Ipilimumab                                     EAP                             RECIST                                                  5        0            5                42         2       0/0       0.0       unk         10.3       no/no
  Danielli                 2012   Ipilimumab                                     EAP                             mWHO                                                    9        0            13               57         2       0/0       0.0       unk         6.0        no/no
  Khan                     2012   Ipilimumab                                     Retrospective                   RECIST, irRC                                            20       0            20               61         7       1/0       5.0       unk         unk        no/no
  Piperno-Neumann          2013   Bevacizumab/temozolomide                       Phase II                        RECIST                                                  35       35           0                55         9       0/0       0.0       3.0         12.0       no/no
  Guenterberg              2011   Bevacizumab/INF-α2b                            Phase II                        RECIST                                                  5        4            1                64         3       0/0       0.0       4.5         10.8       no/no
  Tarhini                  2011   Aflibercept                                    Phase II                        RECIST                                                  9        10           0                57         unk     0/0       0.0       5.7         19.0       yes/no
  Zeldis                   2009   Lenalidomide                                   Phase II                        RECIST                                                  16       unk          unk              53         7       0/0       0.0       unk         unk        no/no
  Solti                    2007   Thalidomide/INF-α2b                            Pilot                           RECIST                                                  6        0            6                59         1       0/0       0.0       3.6         9.0        no/no
  Reiriz                   2004   Thalidomide                                    Phase II                        WHO                                                     5        0            5                59         1       0/0       0.0       unk         unk        yes/no
  Bhatia                   2012   Carboplatin/paclitaxel/sorafenib               Phase II                        RECIST                                                  24       20           4                61         12      0/0       0.0       4.0         11.0       no/no
  Kaempgen                 2012   Fotemustine/sorafenib                          Case series                     Investigator decision[1](#tf1-1){ref-type="table-fn"}   7        unk          unk              unk        unk     3/0       42.0      unk         unk        no/no
  Falchook                 2012   Trametinib                                     Phase I                         RECIST                                                  16       1            15               53         8 (f)   0/0       0.0       1.8         unk        yes/yes (f)
  Kirkwood                 2011   Selumetinib                                    Phase II                        RECIST                                                  7        20           0                57         unk     0/0       0.0       unk         unk        yes/yes (g)
  Mahipal                  2012   Sunitinib                                      Pilot                           RECIST                                                  18       3            17               69         12      1//0      5.0       4.2         8.2        no/no
  Nathan                   2012   Imatinib                                       Phase II                        RECIST                                                  25       24           13               63         unk     2/0 (h)   8.0       3.0         7.4        yes/yes (h)
  Hofmann                  2008   Imatinib                                       Phase II                        RECIST                                                  9        9            3                63         1       0/0       0.0       unk         6.8        yes/yes (i)
  Penel                    2008   Imatinib                                       Phase II                        RECIST                                                  10       6            7                58         1       0/0       0.0       unk         10.8       yes/no

a, only iv-group considered; b, CR patient had lung metastases only; c, 5/64 patients received chemotherapy/IL-2; d, not in all patients; e, OS includes intraarterially treated patients; f, no correlation of GNAQ status and response (GNAQ testing in six patients); g, GNAQ mutated in four, wild type in eight patients; h, c-kit exons 11, 13, and 17 analyzed, both PR patients c-kit wild type; i, c-kit immunohistology; bid, twice daily; EAP, expanded access program; iv, intravenous; ia, intraarterial (hepatic); mon, months; *n*, number of patients; unk, unknown; ORR, overall response rate; CR, rates of complete; PR, partial remission; PFS, progression-free survival; OS, overall survival.

First authors were contacted by email for clarification of objective response assessment.

Response, including CR and PR, was achieved in 39 of 841 patients; ORR was 4.6% (95% CI 3.3--6.3%). No responses were observed in 22/40 studies. Stable (SD) versus progressive disease (PD) was reported over all studies for 184 versus 379 patients (ratio 1:2) while nine studies did not provide information on SD/PD numbers. Median OS was reported in 26/40 studies ranging from 5.2 months in pretreated, predominantly end-stage patients [@b37] to 19.0 months in selected first-line patients [@b38]. Progression-free survival (PFS) was reported in 21/40 studies ranging from 1.8 to 7.1 months.

Single-agent chemotherapeutic regimens (dacarbazine [@b22], fotemustine [@b30],[@b39], DHA-paclitaxel [@b40]) showed ORR below 10% with the exception of a small pilot study (1 CR/4 patients) [@b29]. Notably, four studies with smaller sample sizes observed no PR/CR (temozolomide [@b34],[@b41], camptothecin [@b42], bendamustine [@b43], treosulfan [@b44]). Testing for equal ORR did not detect substantial heterogeneity (*P* = 0.56). The estimated ORR was 3.9% (95% CI 1.8--7.2%) (Fig. [2](#fig02){ref-type="fig"}A). Most of the patients were treated in non-first-line situations.

![Response rates for single-agent chemotherapies (A), combination chemotherapies (B), and chemoimmunotherapies and immunotherapy with ipilimumab (C).](cam40002-0674-f2){#fig02}

The best-investigated combination chemotherapy regimen is gemcitabine/treosulfan, tested in six phase I and II trials (Fig. [2](#fig02){ref-type="fig"}B). An outstanding ORR of 28.6% (one CR, three PR in 14 patients) with OS of 15.3 months, and PFS of 7.1 month [@b45] could not be reproduced by subsequent studies on gemcitabine/treosulfan with more than 20 patients each and histology-proven disease in 4/5 studies [@b21],[@b42],[@b44]--[@b46]. Reports on combination chemotherapies including cisplatin/gemcitabine/treosulfan [@b46],[@b47], dacarbazine/treosulfan [@b48], and carboplatin/paclitaxel/sorafenib [@b49] showed no responses. Analysis of all combination chemotherapies excluding Pföhler et al. [@b45]. for homogeneity reason revealed responses in 9/222 patients (ORR 4.1%; 95% CI 1.9--7.6%).

Chemoimmunotherapy regimens (bleomycin/vincristine/lomustine/dacarbazine \[=BOLD\]/INF-α2b, fotemustine/INF-α2b/IL-2) were studied in four phase II trials with 20--25 patients each, mainly in first-line situations with histology-proven MUM in 3/4 studies [@b50]--[@b53]. The test for equal ORR did not detect substantial heterogeneity (*P* = 0.16); estimated ORR was 10.3% (95% CI: 4.8--18.7%) (Fig. [2](#fig02){ref-type="fig"}C).

Ipilimumab immunotherapy (3 and 10 mg/kg) was analyzed in three expanded access programs and one retrospective single-center study in non-first-line situations [@b37],[@b54]--[@b56]. Two of 56 evaluable patients experienced PR (ORR 3.6%; 95% CI 0.4--12.3%) (Fig. [2](#fig02){ref-type="fig"}C) while 12 patients showed disease stabilization.

Antiangiogenetic treatment strategies using bevacizumab combined with interferon-α2b [@b57], temozolomide [@b58], or the vascular endothelial growth factor (VEGF)-trap aflibercept [@b38] did not show responses in first-line treatment. The antineoplastic and antiangiogenetic drug thalidomide failed to show responses in second-line situations as single agent [@b59] and in combination with interferon-α2b [@b60]. Moreover, lenalidomide, which has antiangiogenetic and immunomodulatory properties, did not induce responses [@b61]. Altogether, in 56 evaluable patients ORR was 0% (95% CI 0--4.7%) (Fig. [3](#fig03){ref-type="fig"}A).

![Response rates for agents with antiangiogenetic effect (A), kinase inhibitors (B), and comparison of all treatment modalities (C).](cam40002-0674-f3){#fig03}

Recent study protocols focus on small molecule kinase inhibitors for targeted therapy of MUM (Fig. [3](#fig03){ref-type="fig"}B). In three studies, imatinib (targets c-kit, platelet-derived growth factor \[PDGF\]) was applied as first- or second-line treatment (300 or 400 mg bid); 2/3 studies showed no responses [@b31],[@b62]. Two PRs (8%) were observed in one study with 25 patients; both responders presented c-kit wild-type status in the assessed metastases [@b32]. Sunitinib (targets PDGF receptor \[PDGFR\], VEGF receptor \[VEGFR\], c-kit, and others) was studied in a pilot trial mainly in second-line situations. One PR (1/18, ORR 5%) and a relatively high proportion of patients in SD status (12/18) were reported [@b63]. Sunitinib was therefore compared to dacarbazine in a randomized phase II trial that revealed no response in the sunitinib (0/37) versus 3 responses in the dacarbazine group (3/37). PFS was not improved in the sunitinib group. Sorafenib (targets RAF, VEGFR, c-kit, PDGFR) was investigated as single agent and in combination with chemotherapy. In a mainly first-line setting sorafenib failed to induce response but 12 of 24 patients showed SD [@b49]. Phase I/II trials on mitogen-activated protein kinase (MEK) inhibitors selumetinib and trametinib that altogether recruited 23 MUM patients showed no responses [@b33],[@b34]. Falchook et al. [@b33] observed SD in 8/16 second-line patients (50%) with SD achievement not correlating with the mutational status. Overall, kinase inhibitors showed responses in 3/146 patients (ORR 2.1%; (95% CI 0.4--5.9%) (Fig. [3](#fig03){ref-type="fig"}B).

Future perspectives
-------------------

Advances in knowledge about genetics and signaling pathways led to initiation of clinical trials with innovative therapeutics. Screening the <http://ClinicalTrials.gov> website for ongoing clinical trials on MUM revealed 15 studies, two of them with randomized design (Table [2](#tbl2){ref-type="table"}). Only two of the phase II studies evaluate chemotherapies (albumin-bound paclitaxel [@b25], liposomal vincristine [@b29]).

###### 

Active/recruiting trials studying treatment approaches for metastatic uveal melanoma as registered on ClinicalTrials.gov.

  ClinicalTrials.gov identifier   Drug                                                                                 Phase   Planned patients   Status                       Sponsor
  ------------------------------- ------------------------------------------------------------------------------------ ------- ------------------ ---------------------------- -------------------------------------------------
  NCT01355120                     Ipilimumab (anti-CTLA4 antibody)                                                     II      41                 Data collection ongoing      University Hospital Essen, Germany
  NCT01034787                     CP-675,206 (anti-CTLA4 antibody)                                                     II      32                 Data collection ongoing      Alberta Health Services, Canada
  NCT01585194                     Ipilimumab (anti-CTLA4 antibody)                                                     II      141                Recruiting                   MD Anderson Cancer Center, US
  NCT01587352                     Vorinostat (histone deacetylase inhibitor)                                           II      32                 Recruiting                   National Cancer Institute, US
  NCT01413191                     Cixutumumab (anti-IGF-1R antibody)                                                   II      32                 Data collection ongoing      National Cancer Institute, US
  NCT01200342                     Genasense/oblimersen (Bcl-2 antisense oligonucleotide) plus carboplatin/paclitaxel   II      30                 Data collection ongoing      MD Anderson Cancer Center, US
  NCT00506142                     Marqibo (liposomal vincristine)                                                      II      50                 Recruiting                   Talon Therapeutics, US
  NCT00738361                     Abraxane (nab-paclitaxel)                                                            II      25                 Completed, results pending   National Comprehensive Cancer Network, Ohio, US
  NCT01252251                     Everolimus (mTOR inhibitor) and pasireotide (somatostatin receptor analog)           II      25                 Recruiting                   Memorial Sloan-Kettering Cancer Center, US
  NCT01200238                     Ganetespib (HSP90 inhibitor)                                                         II      30                 Recruiting                   Dana-Farber Cancer Institute, US
  NCT01143402                     Selumetinib (MEK inhibitor) versus temozolomide                                      II      159                Recruiting                   National Cancer Institute, US
  NCT01430416                     AEB071 (protein kinase C inhibitor)                                                  I       65                 Recruiting                   Novartis Pharmaceuticals, US
  NCT01377025                     Sorafenib versus placebo                                                             II      200                Recruiting                   University Hospital, Essen, Germany
  NCT01801358                     AEB071 (protein kinase C inhibitor) plus MEK162                                      I/II    90                 Not yet recruiting           Novartis Pharmaceuticals, US
  NCT01835145                     Cabozantinib versus temozolomide or dacarbazine                                      II      69                 Not yet recruiting           National Cancer Institute, US

The occurrence of UMs in an immunologically privileged site makes immunotherapy a promising treatment approach. Current data on ipilimumab were gained from retrospective analyses only. One was published at the time of manuscript revision and showed, in line with the previously published studies, an ORR of 5.1% (2/39); SD was observed in 44% (week 12) and 25% (week 23) of patients [@b64]. Anti-CTLA4 antibodies are further assessed in three prospective trials. While two of them are expected to report outcomes soon, another large trial on ipilimumab will not be finished before 2017 (Table [2](#tbl2){ref-type="table"}). PD-1 and PD-L1 have become important targets in cutaneous melanoma. To our knowledge, MUM patients have not been included in trials with PD-1 or PD-L1 antibodies yet. However, as PD-L1 expression is found in MUM cells [@b65] and probably in the tumor environment further investigation of treatment strategies targeting PD-1/PD-L1 in MUM are warranted.

Activating somatic mutations in GNAQ/GNA11, two members of the guanine nucleotide-binding protein family (G-proteins), were found in 83% of UMs [@b66]. Both mutations result in the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway thereby inducing proliferation in the absence of external growth stimuli [@b67]. Hence, blocking this pathway by specific inhibitors may be an effective therapeutic approach for MUM [@b68]--[@b70]. Several kinase inhibitors are currently studied in five phase I/II and II studies. A phase II study presently conducted in the US compares selumetinib versus temozolomide/DTIC with a much noticed interim analysis on PFS; ORR was 15% in the selumetinib-group (7/46) compared to 0% in the temozolomide-group (0/46) and 0% in the cross-over group [@b26]. However, tumor regression without reaching RECIST-defined response was seen in 50% in the selumetinib-group versus 11% in the temozolomide group and 23% in the cross-over group. PFS in week 16 was 43.1% for selumetinib versus 8.5% for temozolomide. Interestingly, responses were also seen in GNAQ/GNA11 (Q209, exon 5) wild-type patients. However, retrospective assessment of codon R183, exon 4 revealed a mutation in the patient with objective response according to RECIST. These promising but preliminary data on MEK inhibition had to be excluded from our numeric analysis as final study outcomes should be awaited [@b26],[@b27].

GNAQ/GNA11 signaling induces activation of phospholipase C (PLC) and protein kinase C (PKC) further downstream of PLC with subsequent MAPK pathway activation [@b71]. There are two trials under way investigating PKC inhibition alone and in combination with MEK inhibition. GNAQ/GNA11 signaling is also linked to the PI3K-AKT pathway in UM, usually in an activating manner resulting in increased cell proliferation and survival [@b71]. Hence inhibition of PI3K or AKT, possibly in combination with MAPK pathway inhibition, appears to be another attractive treatment strategy.

On the basis of promising data on the multikinase inhibitor sorafenib in small case series, a placebo-controlled phase II study is currently conducted in Germany investigating sorafenib versus placebo. Preliminary data on cabozantinib, a c-Met/VEGFR2 inhibitor currently under investigation [@b12], prompted investigators to initiate a randomized phase II study on cabozantinib versus dacarbacine or temozolomide. Search on the <http://ClinicalTrials.gov> website additionally revealed results on one terminated, yet unpublished study analyzing the combination of sunitinib/lenalidomide/cyclophosphamide, which showed no response in 12 patients (NCT00482911).

Mutations in BAP1, a deubiquitinating enzyme located on chromosome 3p, are seen in 85% of high-risk ("class-2") UMs and correlate with development of metastatic disease [@b72]. One substrate of BAP1 is histone H2A; histone-deacetylase inhibitors were shown to reverse the H2A hyperubiquitination caused by BAP1 knock-down in vitro [@b73] and might therefore be a therapeutic strategy [@b74]. The histone-deacetylase inhibitor vorinostat is currently studied in MUM.

Antiapoptotic bcl-2, which is (over)expressed in more than 95% of UMs [@b72], provides another potential target. The bcl-2-antisense oligonucleotide oblimersen is currently under investigation. Upregulation of insulin-like growth factor (IGF)-1 and IGF-1R receptor in UM [@b72] potentially offers the possibility of treatment with the anti-IGF-1R-antibody cixutumumab. Further compounds currently under investigation in phase II studies include the HSP90 inhibitor ganetespib, and the somatostatin receptor analog pasireotide in combination with everolimus. Other treatment approaches such as targeting of somatostatin receptors by octreotid [@b24] and a phase I/II study on pegylated arginine were disappointing [@b28].

Altogether, immunotherapeutics and kinase inhibitors are currently the most investigated agents with encouraging interim results on MEK inhibition.

Discussion
==========

Depending on the genetic signatures of the primary tumor [@b6], up to 50% of UM patients develop metastatic disease. Once metastases occur prognosis is bad and therapeutic options are limited with ORR being considerably low.

The only randomized controlled phase III trial on treatment of MUM (intravenous vs. intraarterial fotemustine) showed improved ORR of liver metastases and prolonged PFS in intraarterially treated patients but similar OS in both groups [@b30]. Response to intravenous fotemustine was as low as 2.4%. Only two phase II studies have up to now been published that were designed as randomized trials with two subgroups [@b22],[@b44]. One of these showed 8% ORR in the dacarbazine group. Relatively high ORRs reported for single-agent or combination chemotherapy in small studies [@b29] are possibly due to selection bias in small patient numbers. Phase II trials on liposomal vincristine and albumin-bound paclitaxel are ongoing but uncertain to reproduce promising results of previous smaller studies [@b29],[@b40].

In our pooled analysis, chemoimmunotherapy shows slightly better tumor responses than chemotherapy. This observation has to be interpreted with caution as our analysis considered first-line and higher line studies as well as studies that did not differentiate the outcome of first- and second-line treated patients. Better OS in the chemoimmunotherapy studies might thus partially be due to a first-line treatment situation in the majority of trials.

New insights into tumor biology led to investigation of immunotherapies, antiangiogenetic agents, and targeted therapies. While ipilimumab is effective in metastatic cutaneous melanoma [@b75], it did not yet appear to be superior to chemotherapy regimens in MUM, possibly because published data have mainly been generated from expanded access programs in non-first-line situations. However, OS of 5.2--10.3 months in pretreated patients might still be promising [@b37],[@b54],[@b56]. Final conclusions can only be drawn from randomized studies, preferably in first-line situations, which are still lacking.

Although VEGF plays a major role in MUM [@b6], treatment regimens focusing on antiangiogenetic agents did not reveal responses in first-line treatment. Nevertheless, pooled OS of 12.7 months appear promising.

Kinase inhibitors including sorafenib, sunitinib, and imatinib did not show any responses in six of nine studies. Promising results from a small case series on sorafenib combined with fotemustine [@b20] led to initiation of a large phase II study of sorafenib the results of which are still pending. The ORR for sunitinib was 5% in a pilot trial [@b63], which, however, could not be confirmed in a subsequent randomized phase II study [@b22].

GNAQ/GNA11 mutations in over 80% of MUM leading to aberrant activation of the MAPK pathway especially makes MEK an attractive therapeutic target [@b6]. Patients recruited in phase I/II studies, however, did not show objective responses upon MEK inhibitor treatment [@b33],[@b34]. Falchook et al. [@b33] did not observe a correlation between the mutational status of GNAQ/GNA11 and clinical response to MEK inhibition but the analyzed exons were not specified in the publication. A phase II study is currently conducted on selumetinib with a promising interim analysis but pending final results [@b26]. According to preliminary data, there is no proven correlation of ORR or PFS with GNAQ/GNA11 mutational status. OS was not significantly improved compared to chemotherapy.

Increasing insight into the biology of MUM has not yet translated into higher ORR. Unexpectedly, a correlation of treatment response to mutational/expression status of molecular targets has not been found in smaller trials [@b32]--[@b34] and ongoing clinical studies [@b26]. So far, there is no evidence of a clinically meaningful survival benefit due to novel targeted agents.

With respect to appallingly low ORR, the question is whether disease stabilizations are treatment related or simply reflecting the natural course of disease [@b13]. None of the currently available therapies has shown prolongation of patients\' OS. Survival data were reported in 75% of the analyzed studies but cannot be compared due to inhomogeneous patients\' characteristics throughout the studies. Only 7/40 publications reported the lengths of metastases-free intervals as primary diagnosis of UM and, if reported, a wide range was seen within and among these studies (0--25 years) [@b39],[@b49],[@b50],[@b53],[@b63],[@b76],[@b77]. As metastases may develop 10 or more years after primary UM, this "dormancy" phenomenon has a high impact on patients\' prognosis [@b78],[@b79]. Moreover, other prognostic parameters such as lactate dehydrogenase, sites of metastases, and patients\' performance status would need to be equally distributed in the studies to allow comparison of survival data.

According to available study data, survival appears to depend on patient- and tumor-related characteristics rather than on the actual treatment [@b3]; it therefore can only be analyzed in randomized studies recruiting patients with comparable characteristics. Given a poor response rate in most of the studies, determining PFS at a certain time point might be a more suitable endpoint. This would require defined staging intervals, which, however, were inhomogeneous throughout the analyzed studies here and therefore not considered in this review.

Conclusion
==========

This review analyzes data of studies on systemic treatment of MUM published between January 1980 and May 2013. Altogether, published data mainly provided low-level evidence. The limited efficacy of current treatment approaches illustrates the high medical need for more effective treatment options in MUM.

To date, no chemotherapeutic, immunotherapeutic, or targeted drug has shown reproducible ORR \>10% or prolonged OS in MUM. Targeted therapeutics as well as immunotherapies might be promising strategies, but need evaluation in prospective trials. Investigation of chemoimmunotherapy-based strategies appeared to become less important, probably due to toxicity profiles although ORR has been superior to all other therapeutic approaches. Most promising preliminary data are available for MEK inhibition. However, these therapeutic regimens should be judged after final data analyses become available. A future goal should be careful design of randomized clinical trials.
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